890977447	890977447	CD	B-NP	O
|	|	NN	I-NP	O
CMH	CMH	NN	I-NP	O
|	|	NN	I-NP	O
48135156	48135156	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
6810020	6810020	CD	B-NP	O
|	|	CC	I-NP	O
9/19/2005	9/19/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/26/2005	10/26/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
ATTENDING	ATTENDING	NNP	B-NP	O
:	:	:	O	O
WAXMAN	WAXMAN	NNP	B-NP	O
,	,	,	O	O
MARCELLUS	MARCELLUS	NNP	B-NP	O
H.	H.	NNP	I-NP	O
MD	MD	NNP	I-NP	O
,	,	,	O	O
PHD	PHD	NNP	B-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
CCU	CCU	NNP	B-NP	O
Service	Service	NNP	I-NP	O
.	.	.	O	O

PRINCIPAL	PRINCIPAL	JJ	B-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
aspirin	aspirin	NN	B-NP	O
allergy	allergy	NN	I-NP	O
.	.	.	O	O

LIST	LIST	NN	B-NP	O
OF	OF	IN	B-PP	O
PROBLEMS	PROBLEMS	NNP	B-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Atrial	Atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Peptic	Peptic	JJ	B-NP	O
ulcer	ulcer	NN	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Colonic	Colonic	JJ	B-NP	O
polyps	polyp	NNS	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Prostate	Prostate	NN	B-NP	O
adenocarcinoma	adenocarcinoma	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Pancreatic	Pancreatic	JJ	B-NP	O
cancer	cancer	NN	I-NP	O
,	,	,	O	O
metastatic	metastatic	JJ	B-ADJP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Mr.	Mr.	NNP	B-NP	O
Galle	Galle	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
67-year-old	67-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	B-protein
risk	risk	NN	I-NP	I-protein
factors	factor	NNS	I-NP	I-protein
including	include	VBG	B-PP	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
CAD	CAD	NN	I-NP	O
history	history	NN	I-NP	O
begins	begin	VBZ	B-VP	O
one	one	CD	B-NP	O
year	year	NN	I-NP	O
ago	ago	RB	B-ADVP	O
when	when	WRB	B-ADVP	O
he	he	PRP	B-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
experience	experience	VB	I-VP	O
resting	rest	VBG	I-VP	O
jaw	jaw	JJ	B-NP	O
pain	pain	NN	I-NP	O
responsive	responsive	JJ	B-ADJP	O
to	to	TO	B-PP	O
two	two	CD	B-NP	O
to	to	TO	I-NP	O
three	three	CD	I-NP	O
sprays	spray	NNS	I-NP	O
of	of	IN	B-PP	O
nitroglycerin	nitroglycerin	NN	B-NP	B-protein
.	.	.	O	O

On	On	IN	B-PP	O
5/10/05	5/10/05	CD	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
presented	present	VBD	B-VP	O
to	to	TO	B-PP	O
Woodterra	Woodterra	NNP	B-NP	O
Raville	Raville	NNP	I-NP	O
Center	Center	NNP	I-NP	O
with	with	IN	B-PP	O
this	this	DT	B-NP	O
pain	pain	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
T	T	NN	B-NP	O
wave	wave	NN	I-NP	O
inversion	inversion	NN	I-NP	O
,	,	,	O	O
ST	ST	JJ	B-NP	O
depressions	depression	NNS	I-NP	O
in	in	IN	B-PP	O
V6	V6	NN	B-NP	O
,	,	,	I-NP	O
V1	V1	NN	I-NP	B-protein
and	and	CC	I-NP	O
aVL	aVL	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	B-protein
markers	marker	NNS	I-NP	I-protein
peaked	peak	VBD	B-VP	O
at	at	IN	B-PP	O
troponin	troponin	NN	B-NP	O
of	of	IN	B-PP	O
29.6	29.6	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
catheterization	catheterization	NN	I-NP	B-protein
lab	lab	NN	I-NP	I-protein
where	where	WRB	B-ADVP	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
90	90	CD	I-NP	O
%	%	NN	I-NP	O
RCA	RCA	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
angioplasty	angioplasty	JJ	B-NP	O
and	and	CC	I-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stent	stent	NN	I-NP	O
placement	placement	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
the	the	DT	B-NP	O
catheterization	catheterization	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
six	six	CD	B-NP	O
weeks	week	NNS	I-NP	O
without	without	IN	B-PP	O
pain	pain	NN	B-NP	O
but	but	CC	B-PP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
two	two	CD	I-NP	O
weeks	week	NNS	I-NP	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
begun	begin	VBN	I-VP	O
to	to	TO	I-VP	O
experience	experience	VB	I-VP	O
increasing	increase	VBG	B-NP	O
jaw	jaw	NN	I-NP	O
pain	pain	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
minimally	minimally	RB	B-ADJP	O
responsive	responsive	JJ	I-ADJP	O
to	to	TO	B-PP	O
nitroglycerin	nitroglycerin	NN	B-NP	O
spray	spray	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
presented	present	VBD	B-VP	O
for	for	IN	B-PP	O
elective	elective	JJ	B-NP	O
recatheterization	recatheterization	NN	I-NP	O
on	on	IN	B-PP	O
1/4	1/4	CD	B-NP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
70	70	CD	B-NP	O
%	%	NN	I-NP	O
LAD	LAD	NN	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
proximal	proximal	JJ	I-NP	O
RCA	RCA	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
Cypher	Cypher	NNP	I-NP	O
stent	stent	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	B-protein
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Integrilin	Integrilin	NNP	B-NP	O
for	for	IN	B-PP	O
24	24	CD	B-NP	O
hours	hour	NNS	I-NP	O
and	and	CC	O	O
sent	send	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	O
for	for	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
desensitization	desensitization	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
taken	take	VBN	I-VP	O
aspirin	aspirin	NN	B-NP	O
for	for	IN	B-PP	O
headaches	headache	NNS	B-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
teens	teen	NNS	I-NP	O
and	and	CC	O	O
developed	develop	VBN	B-NP	O
rashes	rash	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
taken	take	VBN	I-VP	O
aspirin	aspirin	RP	B-PRT	O
a	a	DT	B-NP	O
few	few	JJ	I-NP	O
times	time	NNS	I-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
20s	20s	CD	I-NP	O
and	and	CC	I-NP	O
30s	30s	CD	I-NP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
recalled	recall	VBN	I-NP	O
side	side	NN	I-NP	O
effects	effect	NNS	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
did	do	VBD	B-VP	O
take	take	VB	I-VP	O
12	12	CD	B-NP	O
years	year	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
,	,	,	O	O
a	a	DT	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
indomethacin	indomethacin	NN	B-NP	O
and	and	CC	O	O
reportedly	reportedly	RB	B-VP	O
had	have	VBD	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
inducted	induct	VBN	I-VP	O
into	into	IN	B-PP	O
a	a	DT	B-NP	O
coma	coma	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
for	for	IN	B-PP	O
severe	severe	JJ	B-NP	O
adverse	adverse	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
indomethacin	indomethacin	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
can	can	MD	B-VP	O
not	not	RB	I-VP	O
elaborate	elaborate	VB	I-VP	O
further	further	RBR	B-ADVP	O
on	on	IN	B-PP	O
what	what	WP	B-NP	O
this	this	DT	B-NP	O
reaction	reaction	NN	I-NP	O
was	be	VBD	B-VP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
need	need	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
new	new	JJ	I-NP	O
Cypher	Cypher	NNP	I-NP	O
stent	stent	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
desensitization	desensitization	NN	B-NP	O
.	.	.	O	O

PREADMISSION	PREADMISSION	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Include	Include	NNP	B-NP	O
Plavix	Plavix	NNP	I-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
captopril	captopril	NN	B-NP	O
37.5	37.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
Imdur	Imdur	NNP	B-NP	O
90	90	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Creon	Creon	NNP	B-NP	O
six	six	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	RB	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
4	4	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
,	,	,	O	O
Humalog	Humalog	NNP	B-NP	O
subcutaneous	subcutaneous	JJ	B-ADJP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
,	,	,	O	O
as	as	IN	B-PP	O
needed	need	VBN	B-NP	O
nitroglycerin	nitroglycerin	NN	I-NP	O
sublingual	sublingual	JJ	I-NP	O
tablets	tablet	NNS	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Include	Include	VBP	B-VP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	I-NP	O
penicillin	penicillin	NN	I-NP	B-protein
and	and	CC	I-NP	O
NSAIDs	NSAID	NNS	I-NP	O
which	which	WDT	B-NP	O
produce	produce	VBP	B-VP	O
rash	rash	NN	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
tobacco	tobacco	NN	I-NP	O
,	,	,	I-NP	O
alcohol	alcohol	NN	I-NP	O
or	or	CC	I-NP	O
other	other	JJ	I-NP	O
drug	drug	NN	I-NP	O
use	use	NN	I-NP	O
history	history	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
lives	live	VBZ	B-VP	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
wife	wife	NN	I-NP	O
and	and	CC	O	O
performs	perform	VBZ	B-VP	O
clerical	clerical	JJ	B-NP	O
work	work	NN	I-NP	O
and	and	CC	O	O
can	can	MD	B-VP	O
perform	perform	VB	I-VP	O
activities	activity	NNS	B-NP	O
of	of	IN	B-PP	O
daily	daily	JJ	B-NP	O
living	living	NN	I-NP	O
without	without	IN	B-PP	O
issue	issue	NN	B-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Mother	Mother	NNP	B-NP	O
had	have	VBD	B-VP	O
esophageal	esophageal	JJ	B-NP	O
cancer	cancer	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
father	father	NN	I-NP	O
had	have	VBD	B-VP	O
renal	renal	JJ	B-NP	O
cancer	cancer	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	B-protein
96.9	96.9	CD	I-NP	I-protein
,	,	,	O	O
pulse	pulse	NN	B-NP	O
87	87	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
130/60	130/60	CD	I-NP	O
,	,	,	O	O
O2	O2	NN	B-NP	O
saturation	saturation	NN	I-NP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
being	be	VBG	B-VP	O
thin	thin	JJ	B-NP	O
,	,	,	I-NP	O
fatigued	fatigued	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
icterus	icterus	NN	I-NP	O
,	,	,	O	O
mildly	mildly	RB	B-VP	O
bleeding	bleed	VBG	I-VP	O
gums	gum	NNS	B-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
at	at	IN	B-PP	O
11	11	CD	B-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

III/VI	III/VI	CD	B-NP	O
harsh	harsh	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
base	base	NN	I-NP	O
.	.	.	O	O

III/IV	III/IV	CD	B-NP	O
diastolic	diastolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
base	base	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
lung	lung	NN	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
with	with	IN	B-PP	O
two	two	CD	B-NP	O
ventral	ventral	JJ	I-NP	O
hernias	hernia	NNS	I-NP	O
without	without	IN	B-PP	O
issue	issue	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-NP	O
and	and	CC	I-NP	O
oriented	oriented	JJ	I-NP	O
x3	x3	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
mild	mild	JJ	B-NP	O
1	1	CD	I-NP	O
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
VALUES	VALUES	NNS	I-NP	O
:	:	:	O	O
His	His	PRP$	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
5.4	5.4	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
30.2	30.2	CD	I-NP	I-protein
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
251	251	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

Creatinine	Creatinine	NN	B-NP	O
was	be	VBD	B-VP	O
1.2	1.2	CD	B-NP	O
after	after	IN	B-PP	O
catheterization	catheterization	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
1.3	1.3	CD	B-NP	O
.	.	.	O	O

CK	CK	NN	B-NP	B-protein
was	be	VBD	B-VP	O
42	42	CD	B-NP	O
,	,	,	O	O
troponin	troponin	NN	B-NP	O
0.12	0.12	CD	I-NP	O
.	.	.	O	O

PROCEDURES	PROCEDURES	NNS	B-NP	O
:	:	:	O	O
Catheterization	Catheterization	NN	B-NP	O
went	go	VBD	B-VP	O
without	without	IN	B-PP	O
event	event	NN	B-NP	O
with	with	IN	B-PP	O
stenting	stente	VBG	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
LAD	LAD	NN	I-NP	O
70	70	CD	B-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
with	with	IN	B-PP	O
Cypher	Cypher	NNP	B-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Cardiac	Cardiac	JJ	B-ADJP	O
.	.	.	O	O

Mr.	Mr.	NNP	B-NP	O
Celeste	Celeste	NNP	I-NP	O
cardiac	cardiac	JJ	B-NP	O
catheterization	catheterization	NN	I-NP	O
went	go	VBD	B-VP	O
smoothly	smoothly	RB	B-ADVP	O
with	with	IN	B-PP	O
identified	identify	VBN	B-NP	O
70	70	CD	I-NP	O
%	%	NN	I-NP	O
mid	mid	JJ	I-NP	O
proximal	proximal	JJ	I-NP	O
LAD	LAD	NN	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
proximal	proximal	JJ	B-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
RCA	RCA	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
Cypher	Cypher	NNP	I-NP	O
stent	stent	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Integrelin	Integrelin	NNP	B-NP	O
and	and	CC	O	O
sent	send	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
CCU	CCU	NN	I-NP	B-DNA
.	.	.	O	O

His	His	PRP$	B-NP	O
Plavix	Plavix	NN	I-NP	O
and	and	CC	I-NP	O
Imdur	Imdur	NN	I-NP	O
were	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
as	as	IN	B-PP	O
per	per	IN	B-PP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
and	and	CC	I-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
were	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
for	for	IN	B-PP	O
anticipation	anticipation	NN	B-NP	O
of	of	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
desensitization	desensitization	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
experience	experience	VB	I-VP	O
any	any	DT	B-NP	O
further	further	JJ	I-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
or	or	CC	O	O
jaw	jaw	NN	B-NP	O
pain	pain	NN	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
stay	stay	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
hemodynamically	hemodynamically	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Allergy	Allergy	NNP	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
agreed	agree	VBN	I-VP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
taken	take	VBN	I-VP	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
now	now	RB	B-ADVP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
Cypher	Cypher	NNP	I-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
his	his	PRP$	B-NP	O
vague	vague	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
possible	possible	JJ	B-NP	O
aspirin	aspirin	NN	I-NP	O
allergy	allergy	NN	I-NP	O
and	and	CC	I-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
anaphylactic	anaphylactic	JJ	B-NP	O
shock	shock	NN	I-NP	O
induced	induce	VBN	B-VP	O
by	by	IN	B-PP	O
NSAIDs	NSAID	NNS	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
to	to	TO	I-VP	O
desensitize	desensitize	VB	I-VP	O
him	him	PRP	B-NP	O
to	to	TO	B-PP	O
81	81	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
as	as	IN	B-PP	O
per	per	IN	B-PP	O
protocol	protocol	NN	B-NP	O
defined	define	VBN	B-VP	O
by	by	IN	B-PP	O
Allergy	Allergy	NNP	B-NP	O
Consult	Consult	NNP	I-NP	O
Service	Service	NNP	I-NP	O
with	with	IN	B-PP	O
doubling	double	VBG	B-VP	O
increments	increment	NNS	B-NP	O
starting	start	VBG	B-VP	O
at	at	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
and	and	CC	O	O
going	go	VBG	B-VP	O
to	to	TO	B-PP	O
81	81	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
two	two	CD	B-NP	O
hours	hour	NNS	I-NP	O
every	every	DT	B-NP	O
30	30	CD	I-NP	O
minutes	minute	NNS	I-NP	O
.	.	.	O	O

Epinephrine	Epinephrine	NN	B-NP	O
and	and	CC	I-NP	O
Benadryl	Benadryl	NN	I-NP	O
were	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
at	at	IN	B-PP	O
bedside	bedside	NN	B-NP	O
but	but	CC	O	O
were	be	VBD	B-VP	O
not	not	RB	I-VP	O
required	require	VBN	I-VP	O
because	because	IN	B-SBAR	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
adverse	adverse	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
to	to	TO	B-PP	O
any	any	DT	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
home	home	NN	B-ADVP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
on	on	IN	B-PP	O
all	all	PDT	B-NP	O
his	his	PRP$	I-NP	O
home	home	NN	I-NP	O
medications	medication	NNS	I-NP	O
as	as	IN	B-SBAR	O
previously	previously	RB	B-ADVP	O
prescribed	prescribe	VBN	B-VP	O
plus	plus	CC	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
each	each	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
instructed	instruct	VBN	I-VP	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
important	important	JJ	B-ADJP	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
his	his	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
every	every	DT	B-NP	O
day	day	NN	I-NP	O
because	because	IN	B-SBAR	O
if	if	IN	B-SBAR	O
he	he	PRP	B-NP	O
missed	miss	VBD	B-VP	O
a	a	DT	B-NP	O
dose	dose	NN	I-NP	O
he	he	PRP	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
allergic	allergic	JJ	I-NP	O
reaction	reaction	NN	I-NP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
desensitization	desensitization	NN	I-NP	O
was	be	VBD	B-VP	O
designed	design	VBN	I-VP	O
to	to	TO	B-VP	O
avoid	avoid	VB	I-VP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Captopril	Captopril	NNP	B-NP	O
37.5	37.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
started	start	VBN	I-VP	O
one	one	CD	B-NP	O
day	day	NN	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Lopressor	Lopressor	NN	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Plavix	Plavix	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Imdur	Imdur	NN	B-NP	O
90	90	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
and	and	CC	O	O
q.p.m.	q.p.m.	NN	B-NP	B-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Creon	Creon	NNP	B-NP	O
six	six	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	RB	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
4	4	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Humalog	Humalog	NN	B-NP	O
subcutaneous	subcutaneous	JJ	B-ADJP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
sublingual	sublingual	JJ	B-ADJP	O
as	as	IN	B-PP	O
needed	need	VBN	B-VP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
every	every	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

FOLLOW	FOLLOW	JJ	B-NP	O
UP	UP	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
call	call	VB	I-VP	O
the	the	DT	B-NP	O
Asound	Asound	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
Allergy	Allergy	NNP	I-NP	O
Service	Service	NNP	I-NP	O
for	for	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
appointment	appointment	NN	I-NP	O
within	within	IN	B-PP	O
two	two	CD	B-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
to	to	TO	B-VP	O
contact	contact	VB	I-VP	O
the	the	DT	B-NP	O
Onco/Allergy	Onco/Allergy	NNP	I-NP	O
fellow	fellow	NN	I-NP	O
if	if	IN	B-SBAR	O
he	he	PRP	B-NP	O
experiences	experience	VBZ	B-VP	O
any	any	DT	B-NP	O
itching	itching	NN	I-NP	O
or	or	CC	I-NP	O
rash	rash	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
few	few	JJ	I-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
8-7947134	8-7947134	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Charlie	Charlie	NNP	B-NP	O
Habibi	Habibi	NNP	I-NP	O
Harbba	Harbba	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
Y	Y	NNP	I-NP	O
Tonkan	Tonkan	NNP	I-NP	O
Newsren	Newsren	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
BANUELOS	BANUELOS	NNP	B-NP	O
,	,	,	O	O
MASON	MASON	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
WISCHMANN	WISCHMANN	NNP	B-NP	O
,	,	,	O	O
COY	COY	NNP	B-NP	O
A.	A.	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
9809248	9809248	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
6/6/05	6/6/05	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
10/23/05	10/23/05	CD	B-NP	O

